Cold Spring Harbor Laboratory

Gov. Kathy Hochul speaking with Cold Spring Harbor Laboratory CEO Bruce Stillman during a recent visit. Photo courtesy of Darren McGee/ Office of Governor Kathy Hochul

By Daniel Dunaief

The transition from studying pancreatic cancer’s playbook to attempting new moves to wrestle it into submission is getting closer at Cold Spring Harbor Laboratory, thanks to support from New York State.

Recently, Governor Kathy Hochul (D) announced that the Empire State would contribute $15 million to a new Pancreatic Cancer Center at Cold Spring Harbor Laboratory as a part of the lab’s Foundations for the Future Expansion.

The funds will support the construction of a new center that will continue to try to defeat this insidious type of cancer as CSHL aims to develop new treatments.

“Patients should not feel there’s no chance and no hope” after a pancreatic cancer diagnosis, said David Tuveson, Director of the CSHL Cancer Center and a researcher whose lab has taken innovative approaches to pancreatic cancer. “They are watching the evolution of an area in a disease that previously has been challenging to treat. Through fundamental research, we are coming up with new approaches.”

As CSHL works with human organoids, which are tissues grown from a patient’s own cancer cells that can be used to test the effectiveness of various treatments and any resistance from cancer, animal models, and other techniques, they have moved closer to finding targets that could lead to new therapies.

Any novel treatment would likely involve creating new companies, likely on Long Island, that could develop these treatments, file for patents, and build a commercial presence and infrastructure.

“It’s an investment by the state to accelerate our translational research so we can go from preclinical to clinical,” said Tuveson. “Part of that will be to generate private entities that can focus on turning a lead to first-in-class, first-in-human products. It allows us to build that infrastructure.”

Tuveson has been working on a potential treatment for several years. Other potential treatments are also in the earlier stages of development.

Governor Hochul suggested that the state’s investment fits in the context of an overall goal to boost the local economy with new biotechnology companies.

“New York State is leading on innovative healthcare space, and this funding will advance research to better understand pancreatic cancer – one of the most devastating forms of cancer,” Governor Hochul said in a statement.

Big Picture

The Pancreatic Cancer Center will take a wide range of approaches to this particular type of cancer.

The Center will be, along with Northwell Health, a “pipeline from fundamental discovery science” to clinical trials conducted with hospital partners, explained Bruce Stillman, CEO of Cold Spring Harbor Laboratory.

The center will address early detection as well.

For Tobias Janowitz, Associate Professor and Cancer Center Program Co-Leader at CSHL, the investment means “we can strengthen collaborations between experts in metabolism, immunology, cancer cell biology, and whole body effects of cancer, all of them interconnected and relevant to therapy development in pancreatic cancer.”

Janowitz explained that patients with pancreatic cancer have the highest incidence of cachexia, in which chronic illness causes a reduction in muscle and fat, lowers people’s interest in food and causes extreme and potentially terminal weight loss. Pancreatic cancer patients almost universally experience a loss of appetite and profound weight and muscle loss.

Understanding cachexia in the context of pancreatic cancer will “enable care for patients with other cancers, too,” Janowitz added.

From that perspective, Janowitz hopes the New York State funds could enable discoveries that reach beyond pancreatic cancer.

As an MD/PhD, Janowitz could be involved in the translation of fundamental discoveries into clinical research and, ultimately, clinical care.

Janowitz has a specific interest in optimizing the therapeutic window for patients with pancreatic cancer.

“We are looking for management options that intensify the anti-cancer effect,” while, at the same time, protecting or reconditioning the whole body, Janowitz added.

Janowitz is using special transcriptomics on clinical samples in collaboration with Jon Preall, who leads the genomics core facility.

In a statement, Cold Spring Harbor Laboratory Chair Marilyn Simons described the state funding as a “catalyst to mobilize further private investment in pancreatic cancer research at CSHL.”

Simons added that her father was diagnosed with pancreatic cancer at the age of 75. A doctor offered him an exploratory operation, which enabled him to live another 14 years.

“Few people are so lucky,” Simons added in a statement. “Our wonderful scientists at Cold Spring Harbor are working with Northwell Health and the Feinstein Institutes to help more people get access to the latest biomedical advances.”

Camila dos Santos Photo courtesy of CSHL

By Daniel Dunaief

People often think of and study systems or organs in the body as discrete units. 

In a healthy human body, however, these organs and systems work together, sometimes producing signals that affect other areas.

Recently, Cold Spring Harbor Laboratory Associate Professor Camila dos Santos and graduate students Samantha Henry and Steven Lewis, along with former postdoctoral researcher Samantha Cyrill, published a study in the journal Nature Communications that showed a link in a mouse model between persistent bacterial urinary tract infections and changes in breast tissue.

The study provides information about how a response in one area of the body could affect another far from an infection and could provide women with the kind of information that could inform the way they monitor their health.

To be sure, dos Santos and her graduate students didn’t study the processes in humans, which could be different than they are in mice.

Indeed, they are in the process of establishing clinical studies to check if UTIs in women drive breast alterations.

The body’s response

In this research, the scientists demonstrated that an unresolved urinary tract infection itself wasn’t causing changes in breast tissue, but that the body’s reaction to the presence of the bacteria triggered these changes.

By treating the urinary tract infections, Henry and Lewis showed that breast cells returned to their normal state.

Further, when they didn’t treat the UTI but blocked the molecule TIMP1, which causes collagen deposits and milk duct enlargements, the breast cells returned to their normal state.

The TIMP1 role is “probably the main eureka moment,” said Lewis, who is an MD/ PhD student at Stony Brook University. “It explains how an infection in the bladder can change a faraway tissue.”

Lewis suggested that collagen, among other factors, changes the density of breast tissue. When women get a mammography, doctors are looking for changes in the density of their breasts.

Taking a step back from the link, these graduate students and dos Santos considered whether changes in the breast tissue during an infection could provide an evolutionary benefit.

“From an evolutionary standpoint, there should be some adaptive advantage,” suggested Henry, who is earning her PhD in genetics at Stony Brook University and will defend her thesis in July. Speculating on what this might be, she suggested the mammary gland might change in response to an infection to protect milk production during lactation, enabling a mother to feed her young.

Epidemiological studies

A link between persistent UTIs and breast cancer could show up in epidemiological studies.

Dos Santos and collaborators are exploring such questions in the context of European data and are working with US collaborators to collect this information.

In addition, dos Santos believes women should consider how other ongoing threats to their overall health impact their bodies. Women with clinical depression, for example, have worse prognoses in terms of disease. Humans have health threats beyond UTIs that could predispose them to developing cancer, dos Santos said.

Division of labor

Henry and Lewis took over a study that Samantha Cyrill, the third co-first author on the paper started. When Cyrill finished her postdoctoral work, Henry and Lewis “put on their capes and said, ‘We are going to take this to the end line.’ They are incredible people,” said dos Santos.

They each contributed to the considerable work involved.

Henry primarily analyzed the single cell RNA sequencing data, specifically identifying changes in the epithelial compartment. Gina Jones, a visiting CSHL undergraduate research program student, and Lewis also contributed to this.

Henry also participated in TIMP1 neutralizing antibody treatment in post-lactation involution mice, contributing to tissue collection and staining.

Working with Cyrill and Henry, Lewis contributed to the mouse work, including experiments like neutralizing TIMP1 and CSF3. Lewis also worked with Cyrill on the UTI infections in the animals and with Henry in processing tissues for single cell RNA sequencing and assisted Henry on the sequencing analysis.

While this result is compelling and offers an opportunity to study how an infection in an area of the body can trigger changes in another, dos Santos recognized the inherent risk in a new project and direction that could have either been disconnected or a been a dead end.

“It was an incredible risk,” said dos Santos. She was rejected from at least four different funding opportunities because the research is “so out there,” she said. She tapped into foundations and to CSHL for support.

Back stories

A resident of Brooklyn, Lewis was born in Queens and raised in Scarsdale. He joined the dos Santos lab in March of 2021. One of the appeals of the dos Santos lab was that he wanted to understand how life history events drive disease, especially breast cancer.

A big Mets fan, Lewis, whose current favorite payer is Pete Alonso, is planning to run his third marathon this fall.

Lewis is dating Sofia Manfredi, who writes for Last Week Tonight with John Oliver and accepted an Emmy award on behalf of the staff.

Lewis considers himself Manfredi’s “biggest cheerleader,” while he appreciates how well she listens to him and asks important questions about his work.

As for Henry, she grew up in Greenport. She joined the lab in May of 2020 and is planning to defend her thesis in July.

Her father Joseph Henry owns JR Home Improvements and her mother Christine Thompson worked as a waitress and a bartender in various restaurants.

Henry is married to Owen Roberts, who is a civil engineer and works in the Empire State Building for HNTB as a civil engineer, where he focuses on traffic.

Henry hopes to live in Boston after she graduates. She’s adopted the rooting interests of her husband, who is a fan of Beantown teams, and will support the Bruins and the Celtics. A lifelong Yankees fan, however, Henry, who watched the Bronx Bombers with her father growing up, draws the line at supporting the “Sawx.”

As for the work, Henry and Lewis are excited to see what the lab discovers in the next steps.

“I do think this work is extremely informative, defining a relationship between an infection, UTI, and the mammary gland that has not previously been appreciated,” Henry explained.

“This provides information to the public,” said Henry. “I always think it is worth knowing how different events may impact your body.”

Gabrielle Pouchelon with technician Sam Liebman. Photo by Constance Brukin/CSHL

By Daniel Dunaief

Gabrielle Pouchelon doesn’t need to answer the age-old debate about heredity vs. environment. When it comes to the development of the brain, she’s studying the response both to sensory cues and genetics.

Gabrielle Pouchelon.
Photo courtesy of CSHL

An Assistant Professor who joined Cold Spring Harbor Laboratory in March of 2022, Pouchelon studies the interplay between sensory and neuromodulatory inputs and genetic programs in circuit maturation. She also studies other neuromodulatory inputs, usually associated with states of adulthood, which could control development.

A combination of genetics and environment shapes the way neurons connect in a healthy brain. In people who develop non-neurotypical behaviors, through autism, schizophrenia or other conditions, the development of neurological connections and architecture is likely different.

Researchers have associated genes of susceptibility with schizophrenia and autism spectrum disorders. Scientists believe environmental cues provide the brain with activity that interact with these genetic components.

“We are trying to understand whether we can [intervene] earlier that can have different outcomes at later times,” said Pouchelon. “We are studying ways to intervene with these transient processes and examine whether dysfunctions associated with the disorders are improved.”

During critical periods of development, the brain has a high level of plasticity, where various inputs can alter neurons and their connections. This not only involves building connections, but sometimes breaking them down and rebuilding other ones. As people age, that plasticity decreases, which is why children learn faster than adults in areas such as the acquisition and development of language skills.

While the timing of critical periods is less well-defined in humans and language is a complex function, the ability to learn new languages at a young age reflects the high plasticity of the brain.

Scientists are studying language processes, which are specific to humans, with functional magnetic resonance imaging.

Pouchelon, who isn’t studying language skills, hopes that understanding the architecture of developing brains and how they respond to sensory and neuromodulatory cues could shed light on the studies performed in humans. Since behavioral therapy and pharmaceutical treatments can help children with autism, she believes understanding how external cues affect genetic elements could uncover drug targets to alleviate symptoms of neurodevelopmental disorders at an early age.

Neurons & the environment

From left, technician Sam Liebman, Gabrielle Pouchelon and postdoctoral researcher Dimitri Dumontier. Photo courtesy of Gabrielle Pouchelon

In her lab, which currently includes three researchers but she expects to double within a month, Pouchelon uses sophisticated tools to target not only the effect of the environment, but also to look at the specific neurons that transmit information.

She is trying to “understand at a very precise level what a sensory input means and what are the neurons that integrate that sensory input.”

Sam Liebman, who became a technician in Pouchelon’s lab two years ago after graduating from the University of Vermont, appreciates the work they’re doing and her mentorship.

The lab is “unique and special” because he has that “close relationship” in what is now a smaller lab with Pouchelon, Liebman said.

Growing up in Huntington, Liebman, who hopes to go to graduate school in the fall of 2025, came to Cold Spring Harbor Laboratory for field trips in middle school and high school.

“I idolized this place and this campus,” said Liebman.

Pouchelon has asked for Liebman’s opinion on potential candidates to join the lab, even summer interns.

Fragile X Syndrome

Most of the work Pouchelon conducts is done on animal models. She is mainly studying animals with a mutation linked to Fragile X Syndrome. 

In Fragile X Syndrome, which can affect boys and girls, children can have developmental delays, learning disabilities and social and behavioral problems. Boys, according to the Centers for Disease Control and Prevention, typically have some degree of intellectual disability, while girls can have normal intelligence or some degree of intellectual disability.

Other models for autism exist, such as genetic mutations in the gene Shank3. “We are trying to utilize these models to apply what we understand of development in brains that are healthy and compare them” to the mutated models, Pouchelon explained.

While clinical trials are exploring receptors as drug targets for Fragile X Syndrome, she hopes to find new ones that are selective in early stages of the disease to modify their use depending on the stages of development.

An annoying nerd

Born and raised in Paris, France to a family that showed considerably more artistic talent than she, Pouchelon struggled with games she and her sisters played when they listened to music on the radio and they had to guess the composer.

“I was the one always losing,” said Pouchelon. Her family, including her two older sisters who currently live in France, knew “way more about art and history than I did. I was the nerd scientist.”

When she was young, she was curious and asked a lot of “annoying questions” because she was interested in the “mystery of everything.” In high school, she became interested in the brain.

Pouchelon, who isn’t actively searching for French food but finds the baguettes at the Duck Island Bakery exceptional, lives on the Cold Spring Harbor Laboratory campus with her husband Djeckby “DJ” Joseph, a naturalized American citizen originally from Haiti who works in law enforcement at the VA Hospital in Manhattan, and their two-year old son Theo.

Eager to ensure her son benefits from a multicultural identity, Pouchelon speaks to Theo in French. He also attends on campus day care, where he learns English.

As for the decision to come to Cold Spring Harbor Laboratory, Pouchelon, who conducted her PhD research at the University of Geneva in Switzerland and completed her postdoctoral research at New York University and at Harvard Medical School, is thrilled to discuss her work with the talented and collegial staff at the lab.

Cold Spring Harbor Laboratory, which is known internationally for meetings and courses, is an “exciting place” where scientists conduct cutting edge research.

Joshua Homer. Photo by Constance Burkin

By Daniel Dunaief

Even as some antibiotics and anti cancer treatments help beat back infections and diseases such as cancer, pathogens and diseases can develop resistance that render these treatments less effective.

Researchers at pharmaceutical companies and universities spend considerable time trying to ensure therapies continue to work. Companies make derivatives of existing drugs or they combine drugs to reduce resistance. They also develop new agents to combat drug-resistant tumors.

Using a chemical process that won his mentor K. Barry Sharpless a Nobel Prize, John Moses, a Professor at Cold Spring Harbor Laboratory, has deployed a new version of click chemistry to assemble biologically active compounds quickly and effectively, which could be used for further development into potential therapies.

Akin to fastening a seatbelt or assembling LEGO blocks, click chemistry benefits from an efficient system to create reliable end products, with the additional advantage of minimizing waste products or impurities.

Recently, Research Investigator Joshua Homer, who has been in Moses’s lab for over three years, published a paper in Chemical Science in which he created several libraries of over 150 compounds. He screened these for activity in anticancer or antibiotic assays.

The newer click process, called Accelerated SuFEx Click Chemistry, or ASCC, involves “less synthetic steps,” said Homer. ASCC can use functional groups like alcohols, that are naturally found in numerous commercially available compounds, directly. Homer can and has used commercially available alkyl and aryl alcohols as fragments in this application of ASCC.

This approach “allows us to explore chemical space so much faster,” Homer said.

In an email, Moses suggested that the paper “demonstrates that SuFEx chemistry can be a feasible and speedy approach compared to traditional methods.”

To be sure, the products could still be a long way from concept to bedside benefit.

“It’s important to note that while the chemistry itself shows promise, the actual application in drug development is complex and can take many years,” Moses added.

The research contributed to finding compounds that may be promising in treating various conditions and represent initial findings and potential starting points for further development, Homer added.

Specifically, Homer took inspiration from the structure of combrestastatin A4 when developing microtubule targeting agents.

The chemicals he produced had good activity against drug-resistant cancer cell lines that resist other treatment options.

Homer also modified the structure of dapsone, generating a derivative with greater activity against a strain of M. tuberculosis that is otherwise resistant to dapsone. 

“Strains of bacteria develop resistance to antibiotics,” said Homer. Derivatization of antibiotic structures can generate compounds that maintain activity.

Breast cancer

In creating these compounds, Homer bolted on different commercially available fragments and developed potential nano-molar treatments that could be effective against triple-negative breast cancer.

At this point, he has evaluated two lead agents in two dimensional cell culture and against patient-derived organoids. Homer did this work in collaboration with the lab of CSHL Cancer Center director David Tuveson.

Organoids can help gauge the potential response of a patient’s tumor to various treatments.

Homer found that eight of the microtubule targeting agents were more potent than colchicine against HCT-15. This cancer cell line, he explained, is known to have upregulated efflux, which is a major cause of drug resistance in cancer cells.

His compounds maintained a similar potency between two dimensional cell lines and organoids. Often, compounds are less potent in organoids, which makes this a promising discovery.

Making molecules and screening them for function to discover lead candidates is one of the first steps in the drug discovery process, with considerable optimization and regulatory steps necessary to generate a drug for the clinic.

Promising treatments sometimes also cause cellular damage in healthy tissue, which reduces the potential benefit of any new treatment. Effective cancer drugs are selective for cancer cells over normal cells.

At this point, the molecules Homer creates involve a search for function, he said. “Once we identify the reaction, we can remake our molecule to confirm it is our compound that is causing a reaction.”

Click chemistry doesn’t necessarily lead to solutions, but it enables scientists and drug companies to create and test molecules more rapidly and with considerably less financial investment.

Click solutions

Click chemistry has affected the way Homer thinks about problems outside the lab.

“I think more about doing things quickly and how to tackle the issues we face, rather than using brute force in one direction,” he said. “We can go in lots of directions and probe. We should be looking at all sorts of baskets at once to solve the issues we have.”

Originally from Tauranga, New Zealand, Homer enjoys traveling around the country, visiting new cities and interacting with different people. A resident of Huntington, Homer is looking forward to an upcoming visit from his parents Dave and Debbie and his aunt Carol, who are making their first trip to the continental United States.

“One of my favorite things about being a scientist is that I can bring my parents out of their comfort zone,” he said. His parents live on a small lifestyle block with several sheep and chickens.

Moses lauded the contributions Homer has made to the lab, including providing mentorship to other students.

As for click chemistry, Homer appreciates how the reactions create opportunities even for those without advanced backgrounds in chemistry.

Click chemistry creates the opportunity to help non-scientists understand scientific concepts more easily.

“I can give a high school student the reagents and substrates and they can reliably make biologically active anticancer agents or antibiotics,” he said. “That helps connect science and drug discovery with the community.”

Cold Spring Harbor Laboratory’s Grace Auditorium, One Bungtown Road, Cold Spring Harbor hosts a lecture titled Tomatoes in Space on Wednesday, April 10 from 7 to 9 p.m. HHMI Investigator, and CSHL Director of Graduate Studies Zachary Lippman leads the audience on a captivating journey as he reveals how CRISPR gene-editing technology is shaping the future of agriculture.

From making crops grow in busy cities to reaching for the stars so plants can grow in space, Dr. Lippman’s lecture walks listeners through the importance of diversifying our agricultural system here on Earth, and beyond. Q&A will follow the lecture. Light refreshments will be served. Free but registration required at www.cshl/edu. For more information, call 516-367-8800.

From left, Mikala Egeblad and Xue-Yan He. Photo from Constance Brukin

By Daniel Dunaief

They both have left Cold Spring Harbor Laboratory, but the innovative research they did on Long Island and that they continue to do, is leaving its mark.

From left, Mikala Egeblad and Xue-Yan He at the American Association for Cancer Research (AACR) annual meeting in New Orleans, Louisiana in 2022. Photo from Xue-Yan He

When Xue-Yan He was a postdoctoral researcher in the lab of Mikala Egeblad, who was Associate Professor at CSHL, the tandem, along with collaborators, performed innovative research on mice to examine how stress affected the recurrence and spread of cancer in a mouse model.

In a paper published in late February in the journal Cancer Cell, He, who is currently Assistant Professor of Cell Biology & Physiology at Washington University School of Medicine in St. Louis, discovered that stress-induced neutrophil extracellular traps (NETs), which typically trap and kill bacteria, trigger the spread of cancer.

“The purpose of our study is to find out what stress does to the body” of an animal model of cancer, said He.

The data in mice demonstrated that targeting NETs in stressed animals significantly reduced the risk for metastases, He explained, suggesting that reducing stress should help cancer treatment and prevention. The researchers speculate that drugs preventing NET formation can be developed and used as new treatments to slow or stop cancer’s spread.

To be sure, this finding, which is encouraging and has generated interest among cancer scientists and neurobiologists, involved a mouse model. Any potential application of this research to the diagnosis and treatment of people will take considerably more effort.

“I want to stress that the evidence for the link between stress, NETs, and cancer is from mouse studies,” Egeblad explained. “We will need to design human studies to know for sure whether the link also exists for humans.”

Still, Egeblad hopes that eventually reducing stress or targeting NETs could be options to prevent metastatic recurrence in cancer survivors. “One major challenge is that a cancer diagnosis by itself is incredibly stressful,” she explained. The results of these experiments have attracted considerable attention in the scientific community, where “there is a lot more to learn!” 

Three part confirmation

When she was a postdoctoral researcher, He removed neutrophils from the mice using antibodies. Neutrophils, which are cells in the immune system, produce the NETs when they are triggered by the glucocorticoid stress hormone.

She also injected an enzyme called DNAse to destroy NETs in the test mice. The former CSHL postdoctoral researcher also used genetically engineered mice that didn’t respond to glucocorticoids.

With these approaches, the test mice developed metastasis at a much lower rate than those that had intact NETs. In addition, chronically stressed mice who didn’t have cancer had NETs that modified their lung tissue.

“Stress is doing something to prepare the organs for metastasis,” said He.

Linda Van Aelst, CSHL Professor and a collaborator on the study, suggested that this work validates efforts to approach mental health in the context of cancer.

“Reducing stress should be a component of cancer treatment and prevention,” Van Aelst said in a statement.

After He removed the primary tumor in the mouse models, the stressed mice developed metastatic cancer at a four-fold higher rate than the mice who weren’t stressed but who also previously had cancer.

The CSHL scientists primarily studied breast cancer for this work.

He appreciated the help and support from her colleagues at CSHL. “To really understand the mechanism” involved in the connection between stress and cancer, “you need a mouse model in the lab, an expert in neuroscience and an expert in the cancer field,” she said.

As a neuroscientist, Van Aelst offered suggestions and comments and helped He conduct behavioral tests to determine a mouse’s stress level. The work for this project formed the focus ofHe’s postdoctoral research, which started in 2016 and ended in 2023.

The link between stress and cancer is receiving increasing attention in the scientific community and has attracted attention on social media, He said.

CSHL “provided a great environment to perform all these experiments,” said He. The numerous meetings CSHL hosts and the willingness of principal investigators across departments made the lab “one of the best places” for a postdoctoral scientist.

“If you need anything from a neural perspective or a technical perspective, you can always find a collaborator” at CSHL, He added.

Born and raised in Nanjing, China, He enjoyed living on Long Island, visiting vineyards and trying to explore every state park. In the harbor, He caught blue crabs while her husband Chen Chen, who was a postdoctoral researcher at CSHL in the lab of Camila dos Santos, went fly fishing at Jones Beach.

In her current research, where she manages a lab that includes a senior scientist, a postdoctoral researcher and an undergraduate, He is extending the work she did at CSHL to colorectal cancer, where she is also analyzing how stress affects the spread of cancer.

“When you’re stressed, you can develop gastrointestinal problems, which is why I wanted to switch from breast cancer to colorectal cancer,” she said.

Extensions of the work

As for context for the research at CSHL, Egeblad wrote that doctors treating patients where the known risk of recurrence is high might use NETs in the blood as a biomarker.

The scientists think cancers that tend to metastasize to the liver, lung or spleen are the strongest candidates to determine the effect of NETs and stress on cancer.

“We have not seen any effects of targeting NETs for metastasis to the bone or the brain in our mouse model and similarly, the studies that have linked NETs to metastasis in human patients have mostly been cancer that has spread to the liver or the lung,” Egeblad said.

Egeblad appreciated the “fantastic job” He did on the work and described her former researcher as being “fearless.”

“She found that stress increased metastasis early in her project but it was a lot of work to discover it was the NETs that were responsible and to conduct studies to ensure that the results were applicable to different types of cancer,” Egeblad explained.

While the two researchers have gone to different institutions and are leading other lab efforts, Egeblad said she’d be happy to collaborate with her former student, who shares the same sense of humor.

Egeblad recalled how He ended her talks by telling the audience that her results showed that Egeblad should give her a “long vacation.”

“I think indeed that she has deserved one after all this work!” Egeblad offered.

Cold Spring Harbor Laboratory neuroscientist Arkarup Banerjee is using singing mice, like the one shown here, to understand how our brains control timing and communication. Photo by Christopher Auger-Dominguez

By Daniel Dunaief

Animals don’t have clocks, telling them when and for how long to run on a treadmill, to eat whatever they catch or to call to each other from the tops of trees or the bottom of a forest.

Arkarup Banerjee

The Alston’s singing mouse, which lives in Costa Rica, has a distinctive call that people can hear and that, more importantly, conveys meaning to other members of the species.

Using equipment to monitor neurons when a mouse offers songs of different length, Cold Spring Harbor Assistant Professor Arkarup Banerjee showed that these unusual rodents exhibit a form a temporal scaling that is akin to stretching or relaxing a rubber band. This scaling suggests that their brains are bending their processing of time to produce songs of different lengths.

“People have shown this kind of time stretching phenomenon in monkeys,” said Banerjee. It was unexpected and surprising that the same algorithm was used in the rodent motor cortex to control the flexibility of a motor pattern and action during vocalization.

Using recordings of neuronal activity over many weeks, Banerjee focused on a part of the mouse brain called the orofacial motor cortex (or OMC). He searched for differences in songs with particular durations and tempo.

Banerjee had set up a system in which he played back the recordings of Alston’s singing mice to his test subjects, who then responded to those songs. Mice generally respond with songs that are variable durations compared to when they sing alone.

These mice can adjust duration and tempo of these 10-second long songs while engaged in social communication.

People “do that all the time,” said Banerjee. “We change the volume of how loud we are speaking and we can change the tempo.”

The mice showed some vocal flexibility similar to other animals, including people.

These mice are singing the same song, with varying rhythms over shorter or longer periods of time. It is as if the same person were to sing “Happy Birthday” in 10 seconds or in 15 seconds.

Banerjee would like to know what is it in the mouse’s brain that allows for such flexibility. He had previously shown that the motor cortex is involved in vocal behavior, which meant he knew of at least one region where he could look for clues about how these rodents were controlling the flexibility of their songs.

By tracking the firing pattern of neurons in the OMC, he was able to relate neural activity to what the mice were doing in real time.

Neural activity expands or contracts in time, almost as if time is running faster or slower. These animals are experiencing relative time when it comes to producing their songs as they change their songs through a wide range of durations.

Pre-song activity

Even before an animal sings, Banerjee speculates its brain could be preparing for the sounds it’s going to make, much as we think of the words we want to say in a conversation or our response to a question before we move our mouths to reply or type on a keyboard to respond.

Songs also track with intruder status. An animal in a home cage sings a shorter song than an animal brought into a new cage.

Vocalizations may scale with social rank, which might help attract mates or serve other social purposes.

Females in the lab, which presumably reflect similar trends in the wild, tend to prefer the male that produces a longer song with a higher tempo, which could reflect their physical fitness and their position in the social hierarchy, according to research from Steve Phelps, Professor at the University of Texas at Austin in the Department of Integrative Biology.

Applications

While it’s a long way from the research he’s conducting to any potential human application, Banerjee could envision ways for these studies to shed light on communication processes and disorders.

The motor cortex in humans and primate is a larger region. Problems in these areas, from strokes or injuries, can result in aphasia, or the inability to articulate words properly. Banerjee plans to look at stroke models to see if the Alston’s singing mouse might provide clues about potential diagnostic or therapeutic clues.

“There are ways we can use this particular system to study cognitive deficits that show up” during articulation deficits such as those caused by strokes, said Banerjee.  While he said scientists know the parts list of the brain regions involved in speaking, they don’t yet know how they all interact.

“If we did, we’d have a much better chance of knowing where it fails,” Banerjee  explained. A challenge along this long process is learning how to generalize any finding in mice to humans. While difficult, this is not an impossible extrapolation, he suggested.

An effective model

Banerjee built a model prior to these experiments to connect neural activity with behavior.

“We had an extremely clear hypothesis about what should happen in the neural domain,” he said. “It was pretty gratifying to see that neurons change the way we predicted given the modeling.”

When the paper first came out about eight months ago in the scientific preprint bioRxiv, it received considerable attention from Banerjee’s colleagues working in similar fields. He went to India to give three talks and gave a recent talk at Emory University.

Outside of the lab, Banerjee and his wife Sanchari Ghosh, who live in Mineola, are enjoying watching the growth and development of their son Ahir, who was born a year and a half ago.

“It’s fascinating as a neuroscientist to watch his development and to see how a tiny human being learns about the world,” Banerjee said.

As for his work with this compelling mouse, Banerjee credited Phelps and his post doctoral advisor at New York University, Michael Long for doing important work on this mouse and for encouraging him to pursue research with this species. Long is a co-corresponding author on the paper. “It’s very gratifying to see that the expectation of what we can do with this species is starting to get fulfilled,” said Banerjee. “We can do these interesting and complex experiments and learn something about vocal interactions. I’m excited about the future.”

——————————————————-

SCIENCE ON SCREEN

The Cinema Arts Centre, 423 Park Ave., Huntington continues its Science on Screen series with a mind-expanding exploration of the mysteries of language and communication, featuring a lecture and Q&A with neuroscientist Arkarup Banerjee, of Cold Spring Harbor Laboratory, and a rare big-screen showing of Denis Villeneuve’s profound 2016 drama ARRIVAL on Tuesday, March 26 at 7 p.m..

Dr. Banerjee’s work explores the theme of decoding messages and touches on the fundamental assumptions of reality which are unpacked in the film. Discover how every species and culture’s unique symbols and codes shape our understanding of the world around us, and uncover the intriguing ways in which our brains navigate the limits and possibilities of language.

Tickets are $16, $10 members. To purchase in advance, visit www.cinemaartscentre.org. 

Bruce Stillman. Photo from CSHL

The toxic talk and policies towards immigrants in the United States is hurting American science and could threaten the country’s ability to compete in technology, an important economic driver.

That’s one of several messages Bruce Stillman, Cold Spring Harbor Laboratory President and Chief Executive Officer, shared in an exclusive interview.

The attitude of some Americans towards immigrants, particularly amid the southern border issue, is “scaring a lot of people off, thinking about working in the United States,” said Stillman. Some of these talented immigrants are wondering why they would come to America. “The perception is that the US is not as welcoming as it used to be,” even for the immigration of highly skilled people, he added.

This hostility could have a detrimental top-down effect on science.

Indeed, immigrants have distinguished themselves, earning top prizes in science and accounting for 38 percent of the Nobel Prizes in physics, 34 percent in medicine and 37 percent in chemistry since 1901, according to Forbes.

“This is a very important economic and competitiveness issue,” said Stillman, who grew up in Australia.

It is increasingly difficult to recruit people from certain countries, particularly amid challenges getting visas, Stillman said.

Cold Spring Harbor Laboratory has an offer out to a “very talented scientist” who has been waiting for almost a year to receive a visa, he said.

Many people have an opinion on the way things ought to be, Stillman explained, including issues related to diversity, equity and inclusion.

“The dialog in the US is no longer civil, but now people are emboldened to attack those in leadership positions,” he explained in an email. “It is part of the wider adversarial dialog going on in America.”

Policies in some states like Florida create the impression, even to accomplished and dedicated workers, that the country does not want them to work here.

CSHL embraces “talented scientists who want to work in the US to come to CSHL,” he explained.

Major scientific recession

Apart from immigration policies that exclude a broad swath of people who might otherwise ensure American technological competitiveness, Stillman is also worried about how political logjams in Washington could limit future funding for science.

“The moderates on both sides of Congress need to come together to override those on the left wing of the Democratic party and those on the right wing in the Republican party,” he explained.

Stillman does not understand why most members of Congress don’t vote out the extremes. If everyone in the middle stood up, “they would be lauded by the general public,” Stillman wrote in an email.

Listening to the fringes of science on both sides who attack science raises the risk of maintaining a leadership position.

Still, he maintains that he is optimistic that the general public and the moderate majority will prevail.

Learning from history

As the leader of Cold Spring Harbor Laboratory for 29 years, Stillman recognizes his institution’s role in a dubious chapter in American history.

Indeed, a century ago, the United States passed the Johnson-Reed Act, or the Immigration Act of 1924, which provided a quota that limited the number of immigrants to two percent of the people of each nationality in the country as of the 1890 census. The law excluded immigrants from Asia.

After that law, Cold Spring Harbor Laboratory played a role in this policy by creating a eugenics record office.

CSHL put up a web site 18 years ago to chronicle the lab’s involvement in a period when science was used to justify discriminatory policies.

“We have highlighted on our web site about the eugenics movement so as to educate children and adults about how misunderstanding science, in this case genetics, can lead to dangerous public policy,” he explained in an email.

This year, on the 100th anniversary of the immigration law, the lab plans to highlight the 1924 Immigration Act as something that led to policies that are “not compatible with what the US is about,” he said.

Building for the future

Like other labs, CSHL is competing to earn federal grants from the National Institutes of Health and the National Science Foundation.

The lab needs to raise “considerable amounts of money each year to eep cutting edge science moving forward,” he wrote.

Indeed, CSHL recently started a major expansion on seven acres of land at the top of the campus to build four research buildings. The lab plans to hire about 14 to 16 new faculty to join the current staff of 56 investigators.

These buildings will expand on programs that explore brain-body physiology, which describes how organs such as the stomach and others interact with the brain.

Many diseases, including cancer, upset the normal brain body interactions, he added. Intervening in these circuits can lead to new therapeutics for cancer and for many neurological disorders.

Researchers at CSHL will publish several discoveries in the next few years in this field that represent “important breakthroughs,” Stillman said.

At the end of May and early June, CSHL will host an annual symposium on brain body physiology, which will include a lecture for the general public.

CSHL is pursuing the most ambitious capital campaign in the lab’s history, raising funds to support the construction of new research and education buildings and to increase the endowment to support the science.

The lab is also building another center called NeuroAI that integrates neuroscience, artificial intelligence and computer science. The computational AI effort has “taken on a life of its own,” he explained. “We plan a major effort to understand how our brain does normal computation and then use this knowledge to improve computer programs.”

In the realm of artificial intelligence, CSHL has used a program called alpha fold, which a unit of Google called Deep Mind developed.

This program predicts protein-protein interactions and protein-drug interactions, which helps “transform the way biology is done,” he said.

While the work “accelerates” the science, it doesn’t “replace doing real experiments,” he added.

Zhe Qian

By Daniel Dunaief

Addition and subtraction aren’t just important during elementary school math class or to help prepare tax returns.

As it turns out, they are also important in the molecular biological world of healthy or diseased cells.

Some diseases add or subtract methyl groups, with a chemical formula of CH3, or phosphate groups, which has a phosphorous molecule attached to four oxygen molecules.

Nicholas Tonks. Photo courtesy of CSHL

Adding or taking away these groups can contribute to the progression of a disease that can mean the difference between sitting comfortably and watching a child’s performance of The Wizard of Oz or sitting in a hospital oncology unit, waiting for treatment for cancer.

Given the importance of these units, which can affect the function of cells, researchers have spent considerable time studying enzymes such as kinases, which add phosphates to proteins.

Protein tyrosine phosphatases, which Professor Nicholas Tonks at Cold Spring Harbor Laboratory purified when he was a postdoctoral researcher, removes these phosphate groups.

Recent PhD graduate Zhe Qian, who conducted research for six years in Tonks’s lab while a student at Stony Brook University, published a paper in the journal Genes & Development demonstrating how an antibody that interferes with a specific type of protein tyrosine phosphatase called PTPRD alters the way breast cancer spreads in cell cultures.

“The PTPs are important regulators of the process of signal transduction — the mechanisms by which cells respond to changes in their environment,” explained Tonks. “Disruption of these signal transduction mechanisms frequently underlies human disease.”

To be sure, Tonks cautioned that the study, which provides a proof of concept for the use of antibodies to manipulate signaling output in a cancer cell, is a long way from providing another tool to combat the development or spread of breast cancer.

The research, which formed the basis for Qian’s PhD project, offers an encouraging start on which to add more information.

Blocking the receptor

Qian, who goes by the name “Changer,” suggested that developing a compound or small molecule to inhibit or target the receptor for this enzyme was difficult, which is “why we chose to use an antibody-based method,” he said.

By tying up a receptor on the outside of the cell membrane, the antibody also doesn’t need to enter the cell to reach its target.

The Antibody Shared Resource, led by Research Associate Professor Johannes Yeh, created antibodies to this particular receptor. Yeh created an antibody is shaped like a Y, with two arms with specific attachments for the PTPD receptor.

Once the antibody attaches, it grabs two of these receptors at the same time, causing a dimerization of the protein. Binding to these proteins causes them to lose their functionality and, ultimately, destroys them.

Cell cultures of breast cancer treated with this antibody became less invasive.

Limited presence

One of the potential complications of finding a new target for any treatment is the side effects from such an approach.

If, for example, these receptors also had normal metabolic functions in a healthy cell, inhibiting or killing those receptors could create problematic side effect.

In this case, however,  the targeted receptor is expressed in the spine and the brain. Antibodies normally don’t cross the blood-brain barrier.

Qian and Tonks don’t know if the antibody would affect the normal function of the brain. Further research would help address this and other questions.

Additionally, as with any possible treatment, future research would also need to address whether cancer cells developed resistance to such an approach.

In the time frame Qian explored, the cells in culture didn’t become resistant.

If the potential therapeutic use of this antibody becomes viable, future researchers and clinicians might combine several treatments to develop ways to contain breast cancer.

Eureka moment

In his research, Qian studied the effect of these antibodies on fixed cell, which are dead but still have the biochemical features of a living cell He also studied living cells.

When the antibody attaches to the receptor, it becomes visible through a staining process. Most antibody candidates stain living cells. Only the successful one showed loss-of-signal in living staining.

The antibody Qian used not only limited the ability of the receptor to send a signal, but also killed the receptor. The important moment in his research occurred when he discovered the antibody suppressed cancer cell invasion in cell culture.

Outside of the lab, Qian enjoys swimming, which he does between four and five times per week. Indeed, he combined his athletic and professional pursuits when he recently raised funds for Swim Across America.

“I not only want to do research, but I also want to call more attention to cancer research in the public,” said Qian.

The Swim Across America slogan suggests that each stroke is for someone who “couldn’t be with us” because of cancer. In the lab, Qian thinks each time he pipettes liquids during one of his many experiments it is for someone who couldn’t make it as well.

Qian, who currently lives in Hicksville, grew up in Suchow City, which is a village west of Shanghai and where Cold Spring Harbor Asia is located. 

Qian has been living on Long Island since he arrived in the United States. Qian graduated from Stony Brook University in October and is currently looking for a job in industry.

Looking back, Qian is pleased with the work he’s done and the contribution he’s made to breast cancer research. He believes the antibody approach offers a viable alternative or complement to searching for small molecules that could target or inhibit proteins or enzymes important in the development of cancer.

The 2023 Double Helix Medals Dinner was once again held under the American Museum of Natural History's iconic blue whale model. Photo from CSHL

By Nick Wurm

On November 15, Cold Spring Harbor Laboratory (CSHL) held its 18th annual Double Helix Medals dinner (DHMD) at the American Museum of Natural History in New York City. CBS journalist Lesley Stahl returned to emcee the awards dinner, which honored Neri Oxman & William Ackman and 2018 Nobel laureate Jim Allison. Thanks to the event chairs and donors, the event raised more than $10 million. After receiving the Double Helix Medal, Oxman and Ackman announced an extraordinary gift, further breaking the event’s fundraising record to support scientific research and education at CSHL.

William Ackman & Neri Oxman

Neri Oxman & William Ackman are co-trustees of the Pershing Square Foundation. The organization empowers scientists to take on important social causes, including the environment, cancer, and cognitive health. Ackman is also the CEO of Pershing Square Capital Management and chairman of the Howard Hughes Corporation. Oxman is an innovative designer whose fusions of technology and biology have been featured in museums around the world. Her work has yielded over 150 scientific publications and inventions.

“Something we continue to this day is backing young, talented entrepreneurs who are on a mission to solve an important societal problem,” Ackman says. “We believe in taking risks with incredible scientists who have the ability to tackle these complex problems,” Oxman adds.

Dr. Jim Allison

Dr. Jim Allison is regental professor and chair of the MD Anderson Cancer Center’s Department of Immunology. He won the 2018 Nobel Prize in Physiology or Medicine for pioneering the field of cancer immunotherapy. Since then, his research has led to the development of ipilimumab, an FDA-approved therapy for metastatic melanoma, renal cell carcinoma, and lung cancer.

“The perception of immunology has shifted,” Dr. Allison says. “People used to say, ‘Will immunotherapy ever work?’ We now know it works. Immunotherapy is going to be a part of all cancer therapies for almost every kind of cancer.”

The 2023 DHMD was chaired by Ms. Jamie Nicholls and Mr. O. Francis Biondi, Ms. Barbara Amonson and Dr. Vincent Della Pietra, Drs. Pamela Hurst-Della Pietra and Stephen Della Pietra, Mr. and Mrs. John M. Desmarais, Mr. and Mrs. Jonathan Gray, Mr. and Mrs. Jeffrey E. Kelter, Dr. and Mrs. Tomislav Kundic, Mr. and Mrs. Robert D. Lindsay, Ms. Ivana Stolnik-Lourie and Dr. Robert Lourie, Dr. Marcia Kramer Mayer, Dr. and Mrs. Howard L. Morgan, Drs. Marilyn and James Simons, and Mr. and Mrs. Paul J. Taubman.

Since the inaugural gala in 2006 honoring Muhammed Ali, the DHMD has raised over $60 million to support CSHL’s biological research and education programs.

Author Nick Wurm is a Communications Specialist at Cold Spring Harbor Laboratory.